New Approach to Online Weight Loss Combines GLP-1 Therapy and Ongoing Wellness Monitoring

EdenRx, a telehealth platform launched from Eden Med Spa in Naples, Florida, is describing an integrated approach to online weight loss that combines GLP-1 medication oversight with structured monthly check-ins, secure provider messaging, and optional wellness programs for eligible patients.

The model, available in Florida and New York, positions itself against what the company characterizes as a transactional norm in telehealth — platforms that dispatch medication with limited ongoing clinical contact. EdenRx says its architecture is built around ongoing provider-patient relationships, not one-time prescriptions.

The Role of Ongoing Monitoring

In EdenRx's model, the initial provider approval is the beginning of a care relationship rather than a standalone transaction. After enrollment, patients complete monthly check-in forms that capture current weight, side effect status, medication tolerance, new medical conditions, and questions for the provider team.

This check-in data is reviewed by the treating provider before each refill is approved. Refills are not automatically dispensed — they require explicit provider sign-off after reviewing the patient's most recent health status.

"We treat this as an ongoing relationship," the company noted. "A monthly check-in isn't a formality — it's how the provider monitors whether treatment is still appropriate and how well the patient is tolerating it."

GLP-1 Medications and Clinical Evidence

EdenRx's GLP-1 programs are based on compound semaglutide (a GLP-1 receptor agonist) and compound tirzepatide (a dual GLP-1 + GIP receptor agonist). Both medications have been the subject of landmark clinical trials that have attracted widespread medical and media attention.

The STEP trial program for semaglutide, published in the New England Journal of Medicine, demonstrated approximately 15% mean body weight reduction at 68 weeks in non-diabetic adults (STEP 1). The SURMOUNT trial program for tirzepatide demonstrated up to approximately 22% mean body weight reduction at 72 weeks in non-diabetic adults at the highest dose (SURMOUNT-1). These are group averages from randomized controlled trials — not predictions of individual outcomes.

EdenRx maintains a clinical research reference page (tryedenrx.org/clinical-research) that lists landmark trials with citations and PubMed identifiers for independent verification.

Optional Wellness Programs

For patients who have been approved for GLP-1 programs, EdenRx offers optional wellness add-ons that have been reviewed and approved by the treating provider on a case-by-case basis. These optional additions are separate from the primary GLP-1 program and subject to their own eligibility criteria, state availability, and provider determination.

The company emphasizes that wellness add-ons are neither required nor guaranteed as part of any treatment plan. They are presented to patients only after primary GLP-1 eligibility has been established and provider approval for the specific add-on has been obtained.

Built From In-Person Clinical Experience

EdenRx's parent organization, Eden Med Spa, is a clinical practice in Naples, Florida with existing in-person patient relationships. The telehealth platform was designed to extend the same clinical rigor that characterizes in-person care into a digital delivery model.

This origin — in contrast to platforms built purely from a technology or direct-to-consumer marketing perspective — shapes the EdenRx approach. Providers are licensed in Florida and New York. Medication is dispensed by a licensed U.S. compound pharmacy. No treatment is initiated without individual clinical review.

About EdenRx

EdenRx is a provider-reviewed telehealth platform offering GLP-1 weight loss programs in Florida and New York. For more information, visit tryedenrx.org.